Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

[Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].

Musto D, Martorelli L, Russo M, Esposito G, Amato MR, Esposito P, Riegler G.

Minerva Gastroenterol Dietol. 2010 Dec;56(4):389-95. Italian.

PMID:
21139538
2.

Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.

Savvidaki E, Koukoulaki M, Benou A, Roumeliotou M, Fourtounas C, Kalliakmani P, Papachristou E, Vlachojannis JG, Goumenos D.

Clin Nephrol. 2011 Feb;75(2):107-12.

PMID:
21255539
3.

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.

Smit JW, Jansen GH, de Bruin TW, Erkelens DW.

Am J Cardiol. 1995 Jul 13;76(2):126A-128A.

PMID:
7604787
4.

Role of policosanols in the prevention and treatment of cardiovascular disease.

Varady KA, Wang Y, Jones PJ.

Nutr Rev. 2003 Nov;61(11):376-83. Review.

PMID:
14677572
5.

[Effects of long acting fluvastatin on parameters of lipid metabolism in patients with type 2 diabetes and combined hyperlipidemia].

Kozlov SG, Liakishev AA, Titov VN, Naumov VG.

Kardiologiia. 2004;44(10):60-3. Russian. No abstract available.

PMID:
15477793
6.
7.

Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment.

Fentoğlu O, Sözen T, Oz SG, Kale B, Sönmez Y, Tonguç MO, Gürgan CA, Aykaç Y, Kirzioğlu FY.

Oral Dis. 2010 Oct;16(7):648-54. doi: 10.1111/j.1601-0825.2010.01668.x.

PMID:
20412449
8.
9.

Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.

Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M.

Adv Med Sci. 2009;54(2):177-82. doi: 10.2478/v10039-009-0047-y.

PMID:
20022856
10.

[Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].

Anikin VV, Savin VV, Lupanov VP, Razygraev RA.

Ter Arkh. 2000;72(8):28-30. Russian.

PMID:
11019422
11.

Impact of fluvastatin on hyperlipidemia after renal transplantation.

Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.

Transplant Proc. 2004 Sep;36(7):2141-4.

PMID:
15518777
12.

Drug therapy of hyperlipidemia.

Prihoda JS, Illingworth DR.

Curr Probl Cardiol. 1992 Sep;17(9):545-605. Review. No abstract available.

PMID:
1446461
13.

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T.

J Gastroenterol. 2011 Jan;46(1):101-7. doi: 10.1007/s00535-010-0291-8. Epub 2010 Jul 24.

PMID:
20658156
14.

Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.

Demetriou D, Shabpar A, Böhmig G, Schmaldienst S, Hörl WH, Watschinger B.

Wien Klin Wochenschr. 2000 Apr 21;112(8):358-61.

PMID:
10849941
15.

Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.

Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, Tzioufa V, Dimitrios K.

Indian J Gastroenterol. 2004 Jul-Aug;23(4):131-4.

PMID:
15333967
16.

Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.

Kardiol Pol. 2004 Jun;60(6):567-77. English, Polish.

PMID:
15334157
17.

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group.

Arch Intern Med. 2002 Jul 22;162(14):1568-76.

PMID:
12123399
18.

Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.

Martín-Castillo A, Castells MT, Adánez G, Polo MT, Pérez BG, Ayala I.

Biomed Pharmacother. 2010 Apr;64(4):275-81. doi: 10.1016/j.biopha.2009.06.003. Epub 2009 Oct 22.

PMID:
19932590
19.

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.

Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R.

Aliment Pharmacol Ther. 2006 Jun 1;23(11):1643-7.

20.

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.

Marcelino JJ, Feingold KR.

Am J Med. 1996 Jun;100(6):605-10.

PMID:
8678079
Items per page

Supplemental Content

Write to the Help Desk